Semaglutide will lose patent protection in Brazil, China and India later this month and there are 150 countries where it was never patented as identified by researchers. Using pricing information of other medicines that are recently no longer patented for, researchers calculated the generic manufacturing price for semaglutide. This drug is a role player in Novo Ozempic and Wegovy treatments. The 160 countries that semaglutide isn’t patented for account for 69% of the people with type 2 diabetes on a global scale and of 84% people with clinical obesity.
This means that if one tried to manufacture a low cost drug in or for low and middle income countries, this would invariably boost health outcomes for those patients struggling with obesity and obesity related health problems! The researchers published their research directly and not in a peer-reviewed scientific journal.
Dr. Samuel Cross of Imperial College London, one of the study’s authors, noted that obesity and diabetes are chronic diseases that increase the risk of stroke, diabetes, heart disease, kidney failure, and cancer.
Source;
https://medicalxpress.com/news/2026-03-anti-obesity-treatment-month.html
https://unsplash.com/photos/medicine-box-and-injection-pens-for-medical-use-aLCcungJbrc
Scriveners Online© 